Abstract
Aim
To evaluate the role of neoadjuvant chemoradiation therapy and rescue surgery in the management of unresectable or recurrent duodenal adenocarcinoma.
Methods
Retrospective review of all adults treated with neoadjuvant therapy and rescue surgery for locally unresectable or locally recurrent duodenal adenocarcinoma from 1994 to 2010.
Results
Ten patients received various forms of neoadjuvant therapy prior to operative exploration for potential resection. Six patients presented with locally unresectable disease, while four had local recurrences. Six patients had vascular encasement, three had retroperitoneal extension with vascular invasion, and one had invasion of surrounding organs. Of the six patients with locally advanced disease, preoperative therapy consisted of chemotherapy alone (3) or chemoradiotherapy (3). Of the four patients with local recurrences, preoperative therapy consisted of chemotherapy alone (1), chemoradiotherapy alone (1), chemoradiotherapy after chemotherapy (1), and chemoradiotherapy followed by combination chemotherapy (1). Nine of ten patients became resectable after neoadjuvant therapy. Clinically, two patients had complete responses, and four had partial responses. Histopathology revealed complete pathologic response in two patients and near-complete pathologic response in one (<1 mm of residual disease). Currently, five patients are alive (range 18–83 months postoperatively). All have no evidence of disease.
Conclusion
Neoadjuvant therapy may convert locally unresectable duodenal adenocarcinoma to resectable disease with subsequent prolonged survival.
Similar content being viewed by others
References
Bakaeen FG, Murr MM, Sarr MG, et al.: What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 2000;135:635–641; discussion 641–632.
Solej M, D’Amico S, Brondino G, et al.: Primary duodenal adenocarcinoma. Tumori 2008;94:779–786.
Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
Alwmark A, Andersson A, Lasson A: Primary carcinoma of the duodenum. Ann Surg 1980;191:13–18.
Dabaja BS, Suki D, Pro B, et al.: Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518–526.
Struck A, Howard T, Chiorean EG, et al.: Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol 2009;100:144–148.
Struck A, Howard T, Chiorean EG, et al.: Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol 2009;100:144–148.
Kelsey CR, Nelson JW, Willett CG, et al.: Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1436–1441.
Yeung RS, Weese JL, Hoffman JP, et al.: Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993;72:2124–2133.
Coia L, Hoffman J, Scher R, et al.: Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161–167.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onkendi, E.O., Boostrom, S.Y., Sarr, M.G. et al. Neoadjuvant Treatment of Duodenal Adenocarcinoma: A Rescue Strategy. J Gastrointest Surg 16, 320–324 (2012). https://doi.org/10.1007/s11605-011-1667-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-011-1667-7